A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

This is a study to determine the clinical benefit (how well the drug works), safety, and tolerability of combining varlilumab and nivolumab (also known as Opdivo , BMS-936558). Both drugs target the immune system and may act to promote anti-cancer effects.

本研究旨在评估瓦利单抗（varlilumab）与纳武利尤单抗（nivolumab，又名欧狄沃（Opdivo）、研发代号BMS-936558）联合使用的临床获益（即药物疗效水平）、安全性与耐受性。两类药物均靶向免疫系统，可发挥抗肿瘤效应。